Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios Appoints Maykin Ho, Ph.D., to its Board of Directors

GlobeNewswire June 23, 2015

Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency

Business Wire June 12, 2015

Agios Announces New Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Business Wire June 12, 2015

Agios Announces New Data from Ongoing Phase 1 Dose Escalation and Expansion Trial of AG-221 Showing Durable Clinical Activity in Patients with Advanced Hematologic Malignancies

Business Wire June 12, 2015

Agios Pharmaceuticals Announces FDA Orphan Drug Designation Granted to AG-120 for Treatment of IDH1-Mutant Positive Acute Myelogenous Leukemia

Business Wire June 10, 2015

Agios to Present Clinical and Preclinical Data at the 20th Congress of the European Hematology Association

Business Wire May 21, 2015

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

GlobeNewswire May 18, 2015

Agios Reports First Quarter 2015 Financial Results and Outlines Late-Stage Clinical Development for AG-221 and AG-120

GlobeNewswire May 7, 2015

Agios Pharmaceuticals Selects Third Novel IDH Mutant Inhibitor, AG-881, for Clinical Development

GlobeNewswire April 29, 2015

Agios Pharmaceuticals to Webcast Conference Call of First Quarter 2015 Financial Results on May 7, 2015

GlobeNewswire April 28, 2015

Agios Pharmaceuticals Announces Orphan Drug Designation of AG-348 for Treatment of Pyruvate Kinase Deficiency

GlobeNewswire March 24, 2015

Investment from Flagship Ventures Brings Red Rock Biofuels Closer to Construction of its First Commercial Biofuel Refinery

Business Wire March 17, 2015

Agios Pharmaceuticals to Present at Cowen and Company 35th Annual Health Care Conference on Monday, March 2

GlobeNewswire February 20, 2015

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

GlobeNewswire February 17, 2015

Agios Pharmaceuticals to Webcast Conference Call of Fourth Quarter and Full Year 2014 Financial Results on February 17, 2015

GlobeNewswire February 10, 2015

Agios Pharmaceuticals to Present at the 2015 Leerink Global Healthcare Conference on Wednesday, February 11

GlobeNewswire February 3, 2015

Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration

GlobeNewswire January 12, 2015

Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12

GlobeNewswire January 5, 2015

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

GlobeNewswire December 16, 2014

Agios Pharmaceuticals Announces Pricing of $220 Million Public Offering of Common Stock

GlobeNewswire December 10, 2014